(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Presenting Nintendo's New Pastel Satisfaction Con Tones for Switch Gamers: 3 Upscale Choices - 25 Food varieties to Remember for Your Eating regimen for Ideal Wellbeing
- 3Help Your Efficiency with These Work area Updates
- 4Joshua Made Last-Second Seat Change That Saved His Life
- 5Zelensky sees new Russian attack threat from Belarus
- What to know about voluntary chocolate recall
- Hamas set to elect new terror leader with Hayya, Mashaal in pole position
- Will your baby get a hep B vaccine? What RFK panel's ruling means.
- Which restaurants and fast food chains will be open on Christmas Eve and Christmas Day?
- Air Canada CEO To Resign After Backlash—Here’s Why Communication Skills Is Now A Leadership Requirement
- South Carolina's measles outbreak reaches 434 cases
- Focus on Yourself: Wellbeing and Taking care of oneself Practices
- Pick Your Favored sort of cooking
- Manual for Notorious Fragrances: Immortal Aromas
